Physician profile
Kimberly K Smith
NPI 1518937572
$6,449.21
in general payments reported to CMS, 2019-2025
38 companies · $37.42 in 2025
The $37.42 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $241 · 2021: $1,346 · 2022: $1,785 · 2023: $1,616 · 2024: $633 · 2025: $37.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,577.58 | 2021-2024 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $753.56 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Biohaven Pharmaceuticals, INC. | $626.91 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $485.89 | 2022 | |
| Lilly USA, LLC | $425.82 | 2019-2023 | Emgality, Reyvow |
| Acadia Pharmaceuticals INC | $274.84 | 2019-2023 | Nuplazid |
| Greenwich Biosciences, INC. | $239.16 | 2019-2020 | |
| Pfizer INC. | $223.57 | 2022-2024 | |
| Biogen, INC. | $178.26 | 2019-2022 | |
| Lundbeck LLC | $162.10 | 2021-2024 | Vyepti |
| Neurocrine Biosciences, INC. | $159.40 | 2021-2024 | Ingrezza, Ongentys |
| Allergan, INC. | $123.15 | 2019-2022 | |
| Sk Life Science, INC. | $121.80 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $116.58 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $89.38 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $87.23 | 2019-2022 | |
| Acorda Therapeutics, INC | $82.50 | 2019-2022 | |
| Amgen INC. | $82.25 | 2019-2020 | |
| Genzyme Corporation | $63.58 | 2022 | |
| Kyowa Kirin, INC. | $60.54 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $46.24 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $44.18 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $42.81 | 2022-2023 | Rytary |
| Jazz Pharmaceuticals INC. | $38.69 | 2022 | |
| Eisai INC. | $38.27 | 2019 | |
| Avion Pharmaceuticals | $37.72 | 2022 | |
| Scilex Pharmaceuticals INC. | $36.90 | 2023-2024 | Ztlido |
| Sumitomo Pharma America, INC. | $32.13 | 2024 | Aptiom |
| Csl Behring | $24.66 | 2023 | Hizentra |
| Ucb, INC. | $23.53 | 2021 | |
| Philips North America LLC | $21.26 | 2019 | |
| Janssen Biotech, INC. | $21.00 | 2025 | Tremfya |
| Medtronic USA, INC. | $19.99 | 2019 | |
| Resmed Corp | $18.94 | 2021 | |
| Merz North America, INC. | $18.89 | 2019 | |
| Almatica Pharma LLC | $17.05 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.43 | 2019 | |
| Inspire Medical Systems, INC. | $16.42 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.